Pfizer's Elelyso nabs Australian approval; Judge allows jawbone-risk claims against Novartis;

@FiercePharma: Top story in FiercePharmaMarketing Weds: Who gets the likes when it comes to job hunting? Think J&J, Novartis and Biogen Idec. Article | Follow @FiercePharma

@TracyStaton: Here's an idea for AZ's full-of-promises execs: Tie pay to opportunity cost. More | Follow @TracyStaton

@EricPFierce: German Merck invests €50M in biologics capacity at Italy plant. FiercePharmaManufacturing story | Follow @EricPFierce

@CarlyHFierce: CIA abandons use of vaccine programs for spying. Story from FierceVaccines | Follow @CarlyHFierce

> Elelyso, an enzyme replacement therapy for Gaucher disease developed by Pfizer ($PFE) and Protalix BioTherapeutics ($PLX), won regulatory approval in Japan. Release

> A Minnesota judge decided not to toss out failure-to-warn claims against Novartis ($NVS), related to its cancer drug Aredia and allegations that it can cause osteonecrosis of the jaw. Report

> Purdue Pharma recruited Saeed Motahari to be its senior vice president and chief commercial officer; Motahari had been a VP of U.S. sales and marketing for AbbVie's ($ABBV) specialty brands business. Release

> The drug distributor Celesio, recently purchased by McKesson Corp. ($MCK), rejigged its management team, with CFO Marion Helmes resigning to be replaced by McKesson's Alain Vachon. Report

> Acura Pharmaceuticals ($ACUR) settled a patent fight with Novartis' generics unit Sandoz, allowing the generics maker to roll out its version of the oxycodone drug Aversion under license from Acura. Report

Medical Device News

@FierceMedDev: Neovasc reports higher 1Q revenues, lower expenses and losses. Story | Follow @FierceMedDev

@VarunSaxena2: St. Jude Medical sticking with renal denervation, releases EnligHTN study data at EuroPCR2014. Release | Follow @VarunSaxena2

@MichaelGFierce: Smallest, fastest nanomotor moves drugs and releases them on demand. Story from FierceDrugDelivery | Follow @MichaelGFierce

@EmilyWFierce: Wound-care outfit Healogics is up for grabs with $1B pricetag. Article | Follow @EmilyWFierce

> Cianna picks up $10M to expand its cancer-fighting device. Item

> Wound-care outfit Healogics is up for grabs with $1B pricetag. Report

> Zimmer CEO insists that no salespeople will be cut after Biomet merger. Story

Biotech News

@FierceBiotech: Editors @JohnCFierce, @DamianFierce and @EricPFierce will chat w/ experts and break down #ASCO2014. More to follow. Sponsored by @Covance. | Follow @FierceBiotech

@JohnCFierce: The R&D rankings: Big biotech once again makes Big Pharma look small. Report | Follow @JohnCFierce

@DamianFierce: So, who's going to run $CELG when Bob Hugin hangs it up? More | Follow @DamianFierce

@EmilyMFierce: ICYMI, this week's edition of FierceBiotech Research features lots of ASM2014 news. Report | Follow @EmilyMFierce

> Sarepta bets on DMD drug approval with a $25M plant buy. Article

> Third Rock builds a new West Coast biotech with an eye on cancer drugs. Story

Pharma Manufacturing News

> Global sweep nabs 237 counterfeiting suspects. News

> Moderna names big names to manufacturing advisory board. Item

> Logistics company RXTPL rails at FDA for identifying it in drug seizure report. Article

> Teva recalls drugs made by India's Emcure over lab testing issues. Story

> India to double its drug inspection staff. Report

Vaccines News

> Pandemic flu vaccine research poses risk of unintended release. Story

> Glaxo announces 5-year price freeze for post-GAVI countries. Article

> CIA abandons use of vaccine programs for spying. More

> Sanofi C. diff vaccine shows immune response in PhII trial. Report

> Kymab, Gates Foundation to team up for malaria, HIV antigen discovery. Item

And Finally... Who needs obesity drugs when a grueling, painful diet-and-exercise program works? Report

Suggested Articles

New "gold standard" data could further increase doctors' confidence in multiple myeloma med Darzalex, Johnson & Johnson says.

Could Monday's cancer buyout be a hint about what Sanofi CEO Paul Hudson will unveil at Tuesday's investor confab? Analysts think so.

Three Samsung execs face up to two years in jail for their roles in destroying data and documents at under-fire affiliate Samsung BioLogics.